Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.
PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating
patients with HIV-related Kaposi's sarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation